Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BIO-TECHNE (TECH) Change in Accured Expenses: 2009-2025

Historic Change in Accured Expenses for BIO-TECHNE (TECH) over the last 17 years, with Jun 2025 value amounting to $15.4 million.

  • BIO-TECHNE's Change in Accured Expenses fell 102.56% to -$22.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year decrease of 75.97%. This contributed to the annual value of $15.4 million for FY2025, which is 40.21% down from last year.
  • Latest data reveals that BIO-TECHNE reported Change in Accured Expenses of $15.4 million as of FY2025, which was down 40.21% from $25.8 million recorded in FY2024.
  • In the past 5 years, BIO-TECHNE's Change in Accured Expenses registered a high of $25.8 million during FY2024, and its lowest value of -$24.6 million during FY2023.
  • Its 3-year average for Change in Accured Expenses is $5.5 million, with a median of $15.4 million in 2025.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first tumbled by 292.75% in 2023, then surged by 204.93% in 2024.
  • Yearly analysis of 5 years shows BIO-TECHNE's Change in Accured Expenses stood at $20.5 million in 2021, then crashed by 37.96% to $12.7 million in 2022, then tumbled by 292.75% to -$24.6 million in 2023, then surged by 204.93% to $25.8 million in 2024, then crashed by 40.21% to $15.4 million in 2025.